H.C. Wainwright Downgrades Rapt Therapeutics (RAPT) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. LLY
5. TSLA
6. META
7. FICO
8. CART
9. SPCX
10. MSFT

Go back to H.C. Wainwright Downgrades Rapt Therapeutics (RAPT) to Neutral

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

February 20, 2024 7:30 AM EST

- RAPT to host a conference call today at 8:30 am ET -

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the companys Phase 2b trial of zelnecirnon (RPT193) in atopic... More